highmark glp-1 coverage MCT2D BCBS insurance dropping glp1 :

Participants were randomized 2:1:1:1:1:2:2 to receive placebo or retatrutide at 1 mg, 4 mg (starting at 2 mg), 4 mg (starting at 4 mg), 8 mg (starting at 2 mg), 8 mg (starting at 4 mg), or 12 mg (starting at 2 mg) administered subcutaneously once weekly for 48 weeks

The SURMOUNT-1 trial provides the most comprehensive data

It was not a major reason for discontinuation in the trial, but it represents a side effect category that tirzepatide users do not encounter

It also helps in developing coping strategies, increasing the likelihood of sustained weight loss

Nasal sprays bypass the GI tract and enter the bloodstream through the olfactory mucosa

Sofwave may be used alone or as part of a broader physician-directed strategy that includes skincare or other aesthetic treatments